Hidradenitis suppurativa as seen by the patient

Cover Page

Cite item

Full Text

Abstract

Background. Hidradenitis suppurativa (HS) is a common disease that significantly reduces the quality of life of patients of reproductive age, while its exact prevalence is unknown in most countries due to untimely and poor-quality diagnosis.

Aim. In order to clarify the prevalence of HS, an analysis of the structure of newly identified cases of this disease was carried out in the conditions of the consultative and diagnostic center of the State Research Center of Dermatovenereology and Cosmetology of the Ministry of Health of the Russian Federation for the period 2008–2021 inclusive. In order to study the characteristics of the course of HS, its impact on behavior and receipt of medical care from the patient’s point of view, an anonymous quantitative online survey of patients was conducted. The patient questionnaire “Shin a light on hidradenitis” was used as a basis.

Methods. Аnonymous quantitative online survey of patients was conducted. The patient questionnaire “Shin a light on hidradenitis” was used as a basis.

Results. For the period 2008–2021 exclusively under the section “L73 Other diseases of the hair follicles”, 765 cases were diagnosed in the State Scientific Center for Disease Control and Prevention (0.36% of the total number of all newly diagnosed cases). The diagnosis of GG (ICD code L73.2) was first established only in 59 cases (about 8% of identified cases using code L73). 1035 respondents took part in the survey. The survey revealed that patients with HS are worried about: 66% — swelling, 55% — pain, 38% — purulent discharge and/or blood, 25% of patients note a disturbing look. Most patients rated the severity of pain as moderate (29%) and low (29%) pain, severe and very severe pain — 12 and 7% respectively. Among the treatments used for HH, patients recommended: antibiotics (34%), opening and drainage (32%), prescription corticosteroid creams/ointments (11%), and biologics (4%). In 44% of patients, a visit to a doctor to provide qualified assistance continues; 18% of patients are observed by one doctor (dermatologist and/or surgeon); 9% of patients visited 2–3 doctors before receiving the necessary help.

Conclusion. All over the world, the “search” for a specialist who will correctly diagnose, prescribe adequate treatment and accompany its long process is still a complex and unsolved task. In order to improve the quality of medical care for patients with HH, it is necessary to develop and implement domestic clinical recommendations, as well as the development and implementation of educational programs for interested specialists.

About the authors

Andrey A. Martynov

State Research Center of Dermatovenereology and Cosmetology

Email: aamart@mail.ru
ORCID iD: 0000-0002-5756-2747
SPIN-code: 2613-8597

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Anna A. Vlasova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: avvla@mail.ru
ORCID iD: 0000-0002-7677-1544
SPIN-code: 8802-7325

MD, Cand. Sci. (Med.)

Russian Federation, Moscow

Olesya S. Mishina

Skin and Allergic Diseases Interregional Charitable Public Organization

Email: olesya.mishina@mail.ru
ORCID iD: 0000-0003-1172-4568
SPIN-code: 5365-9340

MD, Cand. Sci. (Med.)

Russian Federation, Moscow

References

  1. Van der Zee HH, Laman JD, de Ruiter L, Dik WA, Prens EP. Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: An in situ and ex vivo study. Br J Dermatol. 2012;166(2):298–305. doi: 10.1111/j.1365-2133.2011.10698.x
  2. Jemec G.B. Hidradenitis Suppurativa. N Engl J Med. . doi:
  3. Poli F, Jemec GBE, Revuz J. Clinical presentation. In: Jemec GBE, Revuz J, Leyden JJ, eds. Hidradenitis suppurativa. Berlin, Heidelberg: Springer; 2006. P. 11–24.
  4. Saunte DM, Boer J, Stratigos A, Szepietowski JC, Hamzavi I, Kim KH, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173(6):1546–1549. doi: 10.1111/bjd.14038
  5. Ingram JR, Woo PN, Chua SL, Ormerod AD, Desai N, Kai AC, et al. Interventions for hidradenitis suppurativa: A Cochrane systematic review incorporating GRADE assessment of evidence quality. Br J Dermatol. 2016;174(5):970–978. doi: 10.1111/bjd.14418
  6. Delany E, Gormley G, Hughes R, McCarthy S, Kirthi S, Markham T, et al. A cross-sectional epidemiological study of hidradenitis suppurativa in an Irish population (SHIP). J Eur Acad Dermatol Venerol. 2018;32(3):467–473. doi: 10.1111/jdv.14686
  7. Canoui-Poitrine F, Revuz JE, Wolkenstein P, Viallette C, Gabison G, Pouge F, et al. Clinical Characteristics of a Series of 302 French Patients with Hidradenitis Suppurativa, with an Analysis of Factors Associated with Disease Severity. J Am Acad Dermatol. 2009;61(1):51–57. doi: 10.1016/j.jaad.2009.02.013
  8. Jemec GB, Kimball AB. Hidradenitis suppurativa: Epidemiology and scope of the problem J Am Acad Dermatol. 2015;73(5 Suppl 1):S4–S7. doi: 10.1016/j.jaad.2015.07.052
  9. Saunte DM, Jemec GB. Hidradenitis Suppurativa: Advances in Diagnosis and Treatment. JAMA. 2017;318(20):2019–2032. doi: 10.1001/jama.2017.16691
  10. Zouboulis CC, Tsatsou F. Disorders of the apocrine sweat glands. In: Goldsmith LA, Katz SI, Cilchrest BA, et al. (eds). Fitzpatrick’s dermatology in general medicine. 8th ed. N.Y.: Mc-Graw Hill; 2012. P. 947–959.
  11. Parks RW, Parks TG. Pathogenesis, clinical features and management of hidradenitis suppurativa. Ann R Coll Surg Engl. 1997;79(2):83–89.
  12. Elkin K, Daveluy S, Avanaki K. Hidradenitis suppurativa: Current understanding, diagnostic and surgical challenges, and developments in ultrasound application. Skin Res Technol. doi:
  13. Werth JM, Jemec GB. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol. 2001;144(4):809–813. doi: 10.1046/j.1365-2133.2001.04137.x
  14. Alikhan A, Lynch P, Eisen D. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60(4):539–563. doi: 10.1016/j.jaad.2008.11.911
  15. nd International Hidradenitis Suppurativa Research Symposium. URL: https://ehsf.eu/events/2nd-international-hidradenitis-suppurativa-research-symposium/
  16. Matusiak Ł, Szczęch J, Kaaz K, Lelonek E, Szepietowski JC. Clinical Characteristics of Pruritus and Pain in Patients with Hidradenitis Suppurativa. Acta Derm Venereol. 20187;98(2):191–194. doi: 10.2340/00015555-2815
  17. The Beacons: Illuminating HS Stories 2023. URL: https://www.shinealightonhs.com/watch-hs-stories#thebeacons
  18. Marzano AV, Genovese G, Casazza G, Moltrasio C, Dapavo P, Micali G, et al. Evidence for a “window of opportunity” in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study. Br J Dermatol. 2021;184(1):133–140. doi: 10.1111/bjd.18983
  19. Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747–761. doi: 10.1016/S0140-6736(23)00022-3

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Distribution of articles found in PubMed using the keyword “hidradenitis suppurativa”, by year of publication

Download (61KB)
Indexing metadata
3. Fig. 2. Dynamics of appealability of patients with a first diagnosis of hidradenitis suppurativa according to the results of observation in the conditions of the State Research Center of Dermatovenereology and Cosmetology, 2008–2021, % of the total number of patients with such a diagnosis

Download (115KB)
Indexing metadata
4. Fig. 3. Results of the distribution of questionnaire responses to the question: «Where on your body do these “bumps,” boils or sores (abscesses) appear? Check all locations that apply to your situation», % of the total number of respondents’ answers

Download (185KB)
Indexing metadata
5. Fig. 4. The results are the distribution of questionnaire responses to the question: «What symptoms do you experience when these “bumps”, boils or ulcers (abscesses) appear? Check all that apply to you», % of the total number of respondents’ answers

Download (168KB)
Indexing metadata
6. Fig. 5. Distribution of questionnaire responses to the question: “If these symptoms cause pain, how serious is it? Select a number that represents the degree of pain”, % of the total number of respondents’ answers

Download (149KB)
Indexing metadata
7. Fig. 6. Results of the distribution of questionnaire responses to the question: «How did these “bumps,” boils or sores (abscesses) affect your skin? Check all that apply to you», %

Download (87KB)
Indexing metadata
8. Fig. 7. Distribution of questionnaire responses to the question: “What areas of your life have been negatively affected by your symptoms? Check all that apply to you”, %

Download (189KB)
Indexing metadata

Copyright (c) 2024 Martynov A.A., Vlasova A.A., Mishina O.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).